poisar

Stocks · News reference

HC Wainwright & Co. Maintains Buy on Ocular Therapeutix, Raises Price Target to $28

BenzingaBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. BenzingaEarnings Transcripts

    Ocular Therapeutix Q3 2026 Earnings Call Transcript

    Ocular Therapeutix (NASDAQ:OCUL) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga

  2. SEC EDGARSEC EDGAR

    8-K filing — OCULAR THERAPEUTIX, INC (OCUL)

    Filed: 2026-11-09 AccNo: 0001104659-26-124159 Size: 191 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers